Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01066819 · ClinicalTrials.gov registry record
PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b
A clinical trial, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- 1,656
- Enrollment target
NCT01066819 is a clinical trial that has completed, run by Hoffmann-La Roche. The registered enrollment target is 1,656 participants.
The verdict
NCT01066819 has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- 1,656 participants
- Enrollment target
Study Summary
This observational study will assess predictors of early on-treatment and sustained virological response in treatment-naïve patients with chronic hepatitis C initiated on treatment with Pegasys (peginterferon alfa-2a) or peginterferon alfa-2b and ribavirin. Data will be collected during the treatment period (24 or 48 weeks) and 12 and 24 weeks after the end of treatment. Target sample size is \<2000.
Interventions
- DRUG Peginterferon alfa-2a [Pegasys]
- DRUG Peginterferon alfa-2b [PegIntron®]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,656 participants |
| Start Date | 2008-01 |
| Est. Completion | 2011-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01066819
The ClinicalTrials.gov registry entry for NCT01066819 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,656 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Peginterferon alfa-2a [Pegasys] is the first listed.
NCT01066819 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01066819 about?
NCT01066819 is a clinical study titled "PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b". This observational study will assess predictors of early on-treatment and sustained virological response in treatment-naïve patients with chronic hepatitis C initiated on treatment with Pegasys (peginterferon alfa-2a) or peginterferon alfa-2b and ribavirin. Data will be collected during the treatmen...
What is the current status of trial NCT01066819?
This trial is currently completed. The enrollment target is 1,656 participants. The study started on 2008-01. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01066819?
The interventions under investigation include: Peginterferon alfa-2a [Pegasys] (DRUG), Peginterferon alfa-2b [PegIntron®] (DRUG).
Who is sponsoring clinical trial NCT01066819?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.